Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Capsugel Unveils Quality Control Laboratory

Published: Monday, December 10, 2012
Last Updated: Monday, December 10, 2012
Bookmark and Share
South Carolina based facility provides global center of excellence for the company.

Capsugel has announced that it has doubled its laboratory capacity with the opening of its new Quality Control Laboratory in Greenwood, SC.

The new laboratory serves as a global resource to its extensive network of manufacturing sites and R&D laboratories located in Boston, Strasbourg and Colmar.

The company invested more than $3 million to create this facility that is the global center of excellence for quality control and testing of all raw materials and specialty testing of finished products for Capsugel sites around the world.

The facility’s opening marks a significant investment that demonstrates Capsugel’s commitment to designing, manufacturing, and delivering premiere healthcare products and services.

“Our new Quality Control Laboratory positions Capsugel for future growth in an increasingly complex regulatory marketplace,” says Guido Driesen, President & CEO of Capsugel.

Driesen continued, “Quality is the hallmark of our business and a core principle at Capsugel that provides added value to our customers. Our thorough testing equates to faster time to market as our products are designed to comply with today’s strict regulations.”

The 9,600 square foot facility is equipped to provide a wide range of analytical and microbial testing, as well as development of color formulations.

With the new capacity, Capsugel has expanded its Global Stability Program with walk-in stability chambers and photo stability chambers.

This critical equipment is used to support the shelf life of the finished products, to register new products in different countries, and to conduct excursion studies to determine the impact of different temperature and humidity conditions on the quality of the capsules.

By the time a product is considered ready for market, it may have gone through up to 23 individual quality tests at the company’s new Quality Control Laboratory.

The facility is the latest in a series of recent upgrades and expansions, as Capsugel grows to meet its increasing global demand for its high quality capsule products.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Capsugel Expanding Pharmaceutical Product Development and Manufacturing Capabilities
Investment accommodates the company’s growing pipeline of pharmaceutical customer projects and brings a broader range of technologies closer to its European customers.
Thursday, August 06, 2015
Capsugel Unveils New Spray-Dried Dispersion Commercial Manufacturing Facility
Significantly expands the commercial manufacturing capability at its Bend, Ore. Site.
Thursday, July 02, 2015
Capsugel Extends Inhaled Biotherapeutics Delivery Capability to Phase 2 Clinical Trials
Company partnering with customers to expand the use of inhalation technologies to treat a wider range of diseases.
Thursday, May 07, 2015
Capsugel Awarded EXCiPACT™ Certifications
First hard capsule manufacturer to receive this important third-party recognition.
Wednesday, October 08, 2014
Capsugel and Cardax to Collaborate on Astaxanthin Products Development
Collaboration leverages Capsugel’s proprietary lipid-based technologies for potential development of consumer health products.
Thursday, August 21, 2014
Capsugel Expands Global Manufacturing for Finished Dosage Forms
DFS unit expands capabilities for hormonal, high-potency compounds.
Thursday, September 26, 2013
Capsugel to Acquire Bend Research
Enhances bioavailability expertise.
Thursday, September 12, 2013
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos